The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

Advancements in lens technology reflect the growing popularity of multifocal lenses

The study underscored a need for tailored approaches among specific patient populations

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.

Sarah M. Thomasy, DVM, PhD, DACVO, discusses the importance of examining how glaucoma affects companion animals like dogs, cats and horses

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale

Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion

The interventional glaucoma mindset can maximise quality of life, but requires clinicians to act fast

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

The European Medicines Agency's new standard procedure allows manufacturers to request advice from medical device expert panels

The link between eye health and mental health may be deeper than previously believed

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

The authors emphasised that consumers and clinicians should be made aware of potential ophthalmic adverse events associated with cosmetics and personal care products